Kelly E. Lake
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kelly E. Lake has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Nathan Luebbering
Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
9 shared publicationsAdam Lane
University of Cincinnati, United States
7 shared publicationsLucille Langenberg
Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
6 shared publicationsStella M. Davies
Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
6 shared publicationsAshley Teusink-Cross
Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
4 shared publicationsSheyar Abdullah
4 shared publications
Latest Publications
- 29 October 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (18) , 2294-2305
Human milk oligosaccharide (2′-FL) modifies the gut microbiome in children after bone marrow transplant
Dysbiosis after allogeneic hematopoietic stem cell transplant (allo-HSCT) predisposes to acute gastrointestinal (GI) graft-versus-host disease (GVHD). Human milk oligosaccharides (HMOs) are prebiotics that establish a favorable intestinal microbiome. We hypothesized that peritransplant HMOs would reduce dysbiosis, and conducted a prospective phase 1/2 study in which 70 patients received oral, daily 2’-fucosyllactose (2’-FL), the most abundant HMO, from start of conditioning through day +30. Primary phase 1 and phase 2 end points were safety and tolerability of 2′-FL and longitudinal preservation of microbiome diversity, respectively. Phase 1 and phase 2 patients with ≥60% adherence were evaluated by correlative analyses. Twenty-nine age-matched patients with available samples in our institutional biorepository served as contemporary controls. 2′-FL was safe and well tolerated on the phase 1 study, which established dosing for the phase 2 study. Shannon diversity was preserved in 2′-FL recipients and declined from baseline to day +30 in controls (P = .04). Generalized linear mixed model analysis revealed higher association of Bifidobacteria and Blautia with 2′-FL (adjusted P< .05). Higher fecal isoleucine (P = .005), tyrosine (P = .05), and taurine (P = .04) were observed in 2′-FL recipients, all associated with protection and regeneration of intestinal epithelium. Lower plasma regulatory islet-derived 3α (P = .053) and suppressor of tumorigenicity 2 levels (P = .038) were observed in 2′-FL recipients compared with controls. Incidence of grade II-IV acute GI GVHD was 0% in 2′-FL recipients compared with 17% in controls (P = .009). Adenovirus reactivation was 0% in 2′-FL recipients compared with 17% in controls (P = .009). 2′-FL is safe and modifies the gut microbiome in children after allo-HSCT. This trial was registered at www.clinicaltrials.gov as #NCT04263597.
- 29 October 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (18) , 2294-2305
Human milk oligosaccharide (2′-FL) modifies the gut microbiome in children after bone marrow transplant
Dysbiosis after allogeneic hematopoietic stem cell transplant (allo-HSCT) predisposes to acute gastrointestinal (GI) graft-versus-host disease (GVHD). Human milk oligosaccharides (HMOs) are prebiotics that establish a favorable intestinal microbiome. We hypothesized that peritransplant HMOs would reduce dysbiosis, and conducted a prospective phase 1/2 study in which 70 patients received oral, daily 2’-fucosyllactose (2’-FL), the most abundant HMO, from start of conditioning through day +30. Primary phase 1 and phase 2 end points were safety and tolerability of 2′-FL and longitudinal preservation of microbiome diversity, respectively. Phase 1 and phase 2 patients with ≥60% adherence were evaluated by correlative analyses. Twenty-nine age-matched patients with available samples in our institutional biorepository served as contemporary controls. 2′-FL was safe and well tolerated on the phase 1 study, which established dosing for the phase 2 study. Shannon diversity was preserved in 2′-FL recipients and declined from baseline to day +30 in controls (P = .04). Generalized linear mixed model analysis revealed higher association of Bifidobacteria and Blautia with 2′-FL (adjusted P< .05). Higher fecal isoleucine (P = .005), tyrosine (P = .05), and taurine (P = .04) were observed in 2′-FL recipients, all associated with protection and regeneration of intestinal epithelium. Lower plasma regulatory islet-derived 3α (P = .053) and suppressor of tumorigenicity 2 levels (P = .038) were observed in 2′-FL recipients compared with controls. Incidence of grade II-IV acute GI GVHD was 0% in 2′-FL recipients compared with 17% in controls (P = .009). Adenovirus reactivation was 0% in 2′-FL recipients compared with 17% in controls (P = .009). 2′-FL is safe and modifies the gut microbiome in children after allo-HSCT. This trial was registered at www.clinicaltrials.gov as #NCT04263597.
- Open Access
- 28 October 2026
- Published by American Society of Hematology in Blood Advances
Patterns of Response to Eculizumab in High-Risk Transplant-Associated Thrombotic Microangiopathy
Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe complication of hematopoietic stem cell transplantation driven by endothelial injury with complement activation and is a leading cause of non-relapse mortality. Terminal complement (C5) blockade with eculizumab improves outcomes in high-risk TA-TMA, yet about one third of patients fail to respond. We studied 85 children and young adults with high-risk TA-TMA treated with pharmacokinetic/pharmacodynamic (PK/PD) guided eculizumab, comparing responders (n=55) and non-responders (n=30). Non-responders exhibited more severe systemic organ injury and markedly inferior survival. PK/PD analysis demonstrated that non-responders required intensified eculizumab dosing to suppress terminal complement activity (sC5b-9). Durable complement control, defined as sustained sC5b-9 normalization reflecting resolution of ongoing complement activation rather than drug-dependent transient suppression, required median 35 days (IQR 21.5-55) of therapy. Non-responders demonstrated persistently elevated proteinuria along with markers of endothelial stress and interferon signaling, including ST2 and CXCL9, despite sustained suppression of sC5b-9 consistent with ongoing endothelial injury not solely explained by circulating terminal complement activity. A subset of patients treated with eculizumab and interferon-γ blocker (emapalumab) demonstrated improved complement pharmacodynamics despite greater baseline complement activation, supporting a pathogenic interaction between interferon signaling and complement-mediated endothelial injury. sC5b-9 remains the only clinically relevant complement biomarker consistently associated with disease risk and outcomes, whereas other quantitative complement component levels did not distinguish responders. Together, these findings indicate that eculizumab non-responders have persistent endothelial injury, identifiable with clinically available biomarkers, and support further investigation of interferon signaling as a potential contributor to treatment resistance.
- 28 October 2026
- Published by American Society of Hematology in Blood Advances
Open AccessPatterns of Response to Eculizumab in High-Risk Transplant-Associated Thrombotic Microangiopathy
Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe complication of hematopoietic stem cell transplantation driven by endothelial injury with complement activation and is a leading cause of non-relapse mortality. Terminal complement (C5) blockade with eculizumab improves outcomes in high-risk TA-TMA, yet about one third of patients fail to respond. We studied 85 children and young adults with high-risk TA-TMA treated with pharmacokinetic/pharmacodynamic (PK/PD) guided eculizumab, comparing responders (n=55) and non-responders (n=30). Non-responders exhibited more severe systemic organ injury and markedly inferior survival. PK/PD analysis demonstrated that non-responders required intensified eculizumab dosing to suppress terminal complement activity (sC5b-9). Durable complement control, defined as sustained sC5b-9 normalization reflecting resolution of ongoing complement activation rather than drug-dependent transient suppression, required median 35 days (IQR 21.5-55) of therapy. Non-responders demonstrated persistently elevated proteinuria along with markers of endothelial stress and interferon signaling, including ST2 and CXCL9, despite sustained suppression of sC5b-9 consistent with ongoing endothelial injury not solely explained by circulating terminal complement activity. A subset of patients treated with eculizumab and interferon-γ blocker (emapalumab) demonstrated improved complement pharmacodynamics despite greater baseline complement activation, supporting a pathogenic interaction between interferon signaling and complement-mediated endothelial injury. sC5b-9 remains the only clinically relevant complement biomarker consistently associated with disease risk and outcomes, whereas other quantitative complement component levels did not distinguish responders. Together, these findings indicate that eculizumab non-responders have persistent endothelial injury, identifiable with clinically available biomarkers, and support further investigation of interferon signaling as a potential contributor to treatment resistance.
- Open Access
- 11 April 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (8) , 1927-1939
Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia
Fanconi anemia (FA) is a rare inherited disorder characterized by progressive bone marrow failure (BMF) and a predisposition to malignancy. Systemic reactive oxygen species (ROS) and increased sensitivity of FA hematopoietic progenitors to ROS play a key role in the pathogenesis of BMF. Treatment with antioxidants improve hematopoietic function in Fancc–/– mice. We report the safety, tolerability, and pharmacokinetics of quercetin, a naturally occurring antioxidant in the first dose-finding phase 1 study for patients with FA. Twelve patients (median age, 7 years [range, 3-21]) received oral quercetin twice daily for 4 months. Quercetin was well tolerated at all dose levels. Allometrically bodyweight-adjusted dose with a maximum adult daily dose of 4000 mg/d was established as the recommended dose of quercetin. Patients in an expansion cohort (n = 18) were treated using this recommended dose for 6 months. A subset of patients showed reduced ROS levels in the peripheral blood (PB) and bone marrow stem cell compartment. Patients in the analysis cohort treated with the recommended dose of quercetin achieved an a priori-defined optimal response of 25% reduction in the PB ROS level compared with baseline. Platelet counts remained stable to slightly improved over the study period (P = .06). Absolute neutrophil counts (P = .01) and hemoglobin levels gradually declined (P = .001). In those with evidence of BMF at baseline, 8 of 15 patients (53%) had a hematological response at some point after quercetin treatment. Fluctuations in counts are common in patients with FA, limiting accurate assessment of the impact of quercetin use in FA. This trial was registered at www.ClinicalTrials.gov as #NCT01720147.
- 11 April 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (8) , 1927-1939
Open AccessPhase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia
Fanconi anemia (FA) is a rare inherited disorder characterized by progressive bone marrow failure (BMF) and a predisposition to malignancy. Systemic reactive oxygen species (ROS) and increased sensitivity of FA hematopoietic progenitors to ROS play a key role in the pathogenesis of BMF. Treatment with antioxidants improve hematopoietic function in Fancc–/– mice. We report the safety, tolerability, and pharmacokinetics of quercetin, a naturally occurring antioxidant in the first dose-finding phase 1 study for patients with FA. Twelve patients (median age, 7 years [range, 3-21]) received oral quercetin twice daily for 4 months. Quercetin was well tolerated at all dose levels. Allometrically bodyweight-adjusted dose with a maximum adult daily dose of 4000 mg/d was established as the recommended dose of quercetin. Patients in an expansion cohort (n = 18) were treated using this recommended dose for 6 months. A subset of patients showed reduced ROS levels in the peripheral blood (PB) and bone marrow stem cell compartment. Patients in the analysis cohort treated with the recommended dose of quercetin achieved an a priori-defined optimal response of 25% reduction in the PB ROS level compared with baseline. Platelet counts remained stable to slightly improved over the study period (P = .06). Absolute neutrophil counts (P = .01) and hemoglobin levels gradually declined (P = .001). In those with evidence of BMF at baseline, 8 of 15 patients (53%) had a hematological response at some point after quercetin treatment. Fluctuations in counts are common in patients with FA, limiting accurate assessment of the impact of quercetin use in FA. This trial was registered at www.ClinicalTrials.gov as #NCT01720147.
- Open Access
- 20 January 2025
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 2 (2)
Kinetics of DNases after hematopoietic stem cell transplant
- 20 January 2025
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 2 (2)
Open AccessKinetics of DNases after hematopoietic stem cell transplant
- Open Access
- 13 January 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (3) , 135.e1-135.e10
Oxidative Stress Early After Hematopoietic Stem Cell Transplant
- 13 January 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (3) , 135.e1-135.e10
Open AccessOxidative Stress Early After Hematopoietic Stem Cell Transplant
- 21 March 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (12) , 1181-1192
A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults
Vitamin A plays a key role in the maintenance of gastrointestinal homeostasis and promotes a tolerogenic phenotype in tissue resident macrophages. We conducted a prospective randomized double-blinded placebo-controlled clinical trial in which 80 recipients of hematopoietic stem cell transplantation (HSCT) were randomized 1:1 to receive pretransplant high-dose vitamin A or placebo. A single oral dose of vitamin A of 4000 IU/kg, maximum 250 000 IU was given before conditioning. The primary end point was incidence of acute graft-versus-host disease (GVHD) at day +100. In an intent-to-treat analysis, incidence of acute GVHD was 12.5% in the vitamin A arm and 20% in the placebo arm (P = .5). Incidence of acute gastrointestinal (GI) GVHD was 2.5% in the vitamin A arm (P = .09) and 12.5% in the placebo arm at day +180. Incidence of chronic GVHD was 5% in the vitamin A arm and 15% in the placebo arm (P = .02) at 1 year. In an “as treated” analysis, cumulative incidence of acute GI GVHD at day +180 was 0% and 12.5% in recipients of vitamin A and placebo, respectively (P = .02), and cumulative incidence of chronic GVHD was 2.7% and 15% in recipients of vitamin A and placebo, respectively (P = .01). The only possibly attributable toxicity was asymptomatic grade 3 hyperbilirubinemia in 1 recipient of vitamin A at day +30, which self-resolved. Absolute CCR9+ CD8+ effector memory T cells, reflecting gut T-cell trafficking, were lower in the vitamin A arm at day +30 after HSCT (P = .01). Levels of serum amyloid A-1, a vitamin A transport protein with proinflammatory effects, were lower in the vitamin A arm. The vitamin A arm had lower interleukin-6 (IL-6), IL-8, and suppressor of tumorigenicity 2 levels and likely a more favorable gut microbiome and short chain fatty acids. Pre-HSCT oral vitamin A is inexpensive, has low toxicity, and reduces GVHD. This trial was registered at www.ClinicalTrials.gov as NCT03202849.
- 21 March 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (12) , 1181-1192
A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults
Vitamin A plays a key role in the maintenance of gastrointestinal homeostasis and promotes a tolerogenic phenotype in tissue resident macrophages. We conducted a prospective randomized double-blinded placebo-controlled clinical trial in which 80 recipients of hematopoietic stem cell transplantation (HSCT) were randomized 1:1 to receive pretransplant high-dose vitamin A or placebo. A single oral dose of vitamin A of 4000 IU/kg, maximum 250 000 IU was given before conditioning. The primary end point was incidence of acute graft-versus-host disease (GVHD) at day +100. In an intent-to-treat analysis, incidence of acute GVHD was 12.5% in the vitamin A arm and 20% in the placebo arm (P = .5). Incidence of acute gastrointestinal (GI) GVHD was 2.5% in the vitamin A arm (P = .09) and 12.5% in the placebo arm at day +180. Incidence of chronic GVHD was 5% in the vitamin A arm and 15% in the placebo arm (P = .02) at 1 year. In an “as treated” analysis, cumulative incidence of acute GI GVHD at day +180 was 0% and 12.5% in recipients of vitamin A and placebo, respectively (P = .02), and cumulative incidence of chronic GVHD was 2.7% and 15% in recipients of vitamin A and placebo, respectively (P = .01). The only possibly attributable toxicity was asymptomatic grade 3 hyperbilirubinemia in 1 recipient of vitamin A at day +30, which self-resolved. Absolute CCR9+ CD8+ effector memory T cells, reflecting gut T-cell trafficking, were lower in the vitamin A arm at day +30 after HSCT (P = .01). Levels of serum amyloid A-1, a vitamin A transport protein with proinflammatory effects, were lower in the vitamin A arm. The vitamin A arm had lower interleukin-6 (IL-6), IL-8, and suppressor of tumorigenicity 2 levels and likely a more favorable gut microbiome and short chain fatty acids. Pre-HSCT oral vitamin A is inexpensive, has low toxicity, and reduces GVHD. This trial was registered at www.ClinicalTrials.gov as NCT03202849.
- Open Access
- 31 August 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (17) , 5137-5151
Intestinal permeability in patients undergoing stem cell transplantation correlates with systemic acute phase responses and dysbiosis
Intestinal permeability may correlate with adverse outcomes during hematopoietic stem cell transplantation (HSCT), but longitudinal quantification with traditional oral mannitol and lactulose is not feasible in HSCT recipients because of mucositis and diarrhea. A modified lactulose:rhamnose (LR) assay is validated in children with environmental enteritis. Our study objective was to quantify peri-HSCT intestinal permeability changes using the modified LR assay. The LR assay was administered before transplant, at day +7 and +30 to 80 pediatric and young adult patients who received allogeneic HSCT. Lactulose and rhamnose were detected using urine mass spectrometry and expressed as an L:R ratio. Metagenomic shotgun sequencing of stool for microbiome analyses and enzyme-linked immunosorbent assay analyses of plasma lipopolysaccharide binding protein (LBP), ST2, REG3α, claudin1, occludin, and intestinal alkaline phosphatase were performed at the same timepoints. L:R ratios were increased at day +7 but returned to baseline at day +30 in most patients (P = .014). Conditioning regimen intensity did not affect the trajectory of L:R (P = .39). Baseline L:R ratios did not vary with diagnosis. L:R correlated with LBP levels (r2 = 0.208; P = .0014). High L:R ratios were associated with lower microbiome diversity (P = .035), loss of anaerobic organisms (P = .020), and higher plasma LBP (P = .0014). No adverse gastrointestinal effects occurred because of LR. Intestinal permeability as measured through L:R ratios after allogeneic HSCT correlates with intestinal dysbiosis and elevated plasma LBP. The LR assay is well-tolerated and may identify transplant recipients who are more likely to experience adverse outcomes.
- 31 August 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (17) , 5137-5151
Open AccessIntestinal permeability in patients undergoing stem cell transplantation correlates with systemic acute phase responses and dysbiosis
Intestinal permeability may correlate with adverse outcomes during hematopoietic stem cell transplantation (HSCT), but longitudinal quantification with traditional oral mannitol and lactulose is not feasible in HSCT recipients because of mucositis and diarrhea. A modified lactulose:rhamnose (LR) assay is validated in children with environmental enteritis. Our study objective was to quantify peri-HSCT intestinal permeability changes using the modified LR assay. The LR assay was administered before transplant, at day +7 and +30 to 80 pediatric and young adult patients who received allogeneic HSCT. Lactulose and rhamnose were detected using urine mass spectrometry and expressed as an L:R ratio. Metagenomic shotgun sequencing of stool for microbiome analyses and enzyme-linked immunosorbent assay analyses of plasma lipopolysaccharide binding protein (LBP), ST2, REG3α, claudin1, occludin, and intestinal alkaline phosphatase were performed at the same timepoints. L:R ratios were increased at day +7 but returned to baseline at day +30 in most patients (P = .014). Conditioning regimen intensity did not affect the trajectory of L:R (P = .39). Baseline L:R ratios did not vary with diagnosis. L:R correlated with LBP levels (r2 = 0.208; P = .0014). High L:R ratios were associated with lower microbiome diversity (P = .035), loss of anaerobic organisms (P = .020), and higher plasma LBP (P = .0014). No adverse gastrointestinal effects occurred because of LR. Intestinal permeability as measured through L:R ratios after allogeneic HSCT correlates with intestinal dysbiosis and elevated plasma LBP. The LR assay is well-tolerated and may identify transplant recipients who are more likely to experience adverse outcomes.
- Open Access
- 1 March 2021
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 27 (3) , S118-S120
Circulating Endothelial Cells for Investigation of Endothelial Injury Mechanisms in Pediatric Hematopoietic Cell Transplant (HCT)
- 1 March 2021
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 27 (3) , S118-S120
Open AccessCirculating Endothelial Cells for Investigation of Endothelial Injury Mechanisms in Pediatric Hematopoietic Cell Transplant (HCT)
- Open Access
- 1 December 2018
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 24 (12) , 2418-2424
Antibiotic Exposure and Reduced Short Chain Fatty Acid Production after Hematopoietic Stem Cell Transplant
- 1 December 2018
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 24 (12) , 2418-2424
Open AccessAntibiotic Exposure and Reduced Short Chain Fatty Acid Production after Hematopoietic Stem Cell Transplant